GAINESVILLE, Fla., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will participate in the Phacilitate Cell & Gene Therapy Forum 2015. On Tuesday, January 27, 2015 in Washington, D.C., AGTC executives will take part in the following sessions:
-
At 11:10am, AGTC Vice President & Chief Business Officer Dan Menichella will give a presentation entitled "AGTC's Gene Therapy Platform for Orphan Ophthalmic Indications" as part of the Forum's Cell & Gene Therapy Technology Showcases.
- At 3:10pm, AGTC Senior Director, Process Development David R. Knop, PhD will co-present with SAFC Carlsbad Senior Manager, Program Manager, Marc Gaal in a session entitled "How are the tools and services sectors preparing to support large scale gene therapy manufacture?"
AGTC and SAFC Commercial (SAFC), the Sigma-Aldrich Corporation (Nasdaq:SIAL) business unit that manufactures specialty chemicals and biologics for commercial life science applications, have an agreement to provide gene therapy manufacturing services to companies developing gene-based therapies.
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology. AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC has recently begun pre-clinical development of treatments for wet AMD using the company's experience in ophthalmology to expand into disease indications with larger markets.